Targeting the androgen receptor signaling pathway in advanced prostate cancer
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting the androgen receptor signaling pathway in advanced prostate cancer
Authors
Keywords
-
Journal
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
Volume -, Issue -, Pages -
Publisher
Oxford University Press (OUP)
Online
2022-04-08
DOI
10.1093/ajhp/zxac105
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- NCCN Guidelines Insights: Prostate Cancer, Version 1.2021
- (2021) Edward Schaeffer et al. Journal of the National Comprehensive Cancer Network
- Treatment Strategies for Metastatic Castration-Sensitive Prostate Cancer: From “All-Comers” to “Personalized” Approach
- (2021) Kenichi Harada et al. OncoTargets and Therapy
- Triple-arm androgen blockade for advanced prostate cancer: a review
- (2021) Milap H. Desai et al. MEDICAL ONCOLOGY
- Androgen receptor degraders overcome common resistance mechanisms developed during prostate cancer treatment
- (2020) Steven Kregel et al. NEOPLASIA
- Cross-resistance among next generation anti-androgen drugs through the AKR1C3/AR-V7 axis in advanced prostate cancer
- (2020) Jinge Zhao et al. MOLECULAR CANCER THERAPEUTICS
- Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer
- (2020) Cora N. Sternberg et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2020) C. Parker et al. ANNALS OF ONCOLOGY
- Darolutamide as a second-generation Androgen receptor inhibitor in the treatment of prostate cancer
- (2020) Ali Abbasi et al. CURRENT MOLECULAR MEDICINE
- Apalutamide and Overall Survival in Prostate Cancer
- (2020) Matthew R. Smith et al. EUROPEAN UROLOGY
- Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide
- (2020) Karim Fizazi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antibiotic-induced epileptic seizures: mechanisms of action and clinical considerations
- (2020) Pitchaya Wanleenuwat et al. SEIZURE-EUROPEAN JOURNAL OF EPILEPSY
- Evaluation of Fall and Fracture Risk Among Men With Prostate Cancer Treated With Androgen Receptor Inhibitors
- (2020) Zin W. Myint et al. JAMA Network Open
- Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer
- (2019) Karim Fizazi et al. NEW ENGLAND JOURNAL OF MEDICINE
- It Is Not Necessary to Discontinue Seizure Threshold–Lowering Medications Prior to Myelography
- (2019) M. Krupa et al. AMERICAN JOURNAL OF NEURORADIOLOGY
- Enzalutamide, apalutamide, or darolutamide: are apples or bananas best for patients?
- (2019) Celestia Higano Nature Reviews Urology
- ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer
- (2019) Andrew J. Armstrong et al. JOURNAL OF CLINICAL ONCOLOGY
- Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer
- (2019) Ian D. Davis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer
- (2019) Kim N. Chi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Management of Osteoporosis in Survivors of Adult Cancers With Nonmetastatic Disease: ASCO Clinical Practice Guideline
- (2019) Charles L. Shapiro et al. JOURNAL OF CLINICAL ONCOLOGY
- Prevention, Treatment, and Monitoring of Seizures in the Intensive Care Unit
- (2019) Micheal Strein et al. Journal of Clinical Medicine
- Second-Generation Antiandrogens: From Discovery to Standard of Care in Castration Resistant Prostate Cancer
- (2019) Meghan A. Rice et al. Frontiers in Oncology
- Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial
- (2019) Daniel J Khalaf et al. LANCET ONCOLOGY
- Blood-brain barrier penetration of [14C]darolutamide compared with [14C]enzalutamide in rats using whole body autoradiography.
- (2018) Christian Zurth et al. JOURNAL OF CLINICAL ONCOLOGY
- Optimizing Anticancer Therapy in Metastatic Non-Castrate Prostate Cancer: American Society of Clinical Oncology Clinical Practice Guideline
- (2018) Michael J. Morris et al. JOURNAL OF CLINICAL ONCOLOGY
- Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer
- (2018) Maha Hussain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer
- (2018) Matthew R. Smith et al. NEW ENGLAND JOURNAL OF MEDICINE
- Metastatic Prostate Cancer
- (2018) Oliver Sartor et al. NEW ENGLAND JOURNAL OF MEDICINE
- Seizure Rates in Enzalutamide-Treated Men With Metastatic Castration-Resistant Prostate Cancer and Risk of Seizure
- (2018) Susan Slovin et al. JAMA Oncology
- Combined N‐terminal androgen receptor and autophagy inhibition increases the antitumor effect in enzalutamide sensitive and enzalutamide resistant prostate cancer cells
- (2018) Benedikt Kranzbühler et al. PROSTATE
- EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer
- (2017) Philip Cornford et al. EUROPEAN UROLOGY
- Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study
- (2017) Tomasz M. Beer et al. EUROPEAN UROLOGY
- The Diagnosis and Treatment of Prostate Cancer
- (2017) Mark S. Litwin et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer
- (2017) Wanling Xie et al. JOURNAL OF CLINICAL ONCOLOGY
- Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
- (2017) Karim Fizazi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Management of Anticoagulation in Patients With Prostate Cancer Receiving Enzalutamide
- (2017) Joseph J. Shatzel et al. Journal of Oncology Practice
- Enzalutamide in castration-resistant prostate cancer patients with visceral disease in the liver and/or lung: Outcomes from the randomized controlled phase 3 AFFIRM trial
- (2016) Yohann Loriot et al. CANCER
- Androgen receptor targeted therapies in castration-resistant prostate cancer: Bench to clinic
- (2016) Yusuke Imamura et al. INTERNATIONAL JOURNAL OF UROLOGY
- Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer
- (2016) Susan Halabi et al. JOURNAL OF CLINICAL ONCOLOGY
- Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
- (2016) Nicholas D James et al. LANCET
- Characteristics and predictors of fatigue among men receiving androgen deprivation therapy for prostate cancer: a controlled comparison
- (2016) Ashley M. Nelson et al. SUPPORTIVE CARE IN CANCER
- Adverse effects of androgen-deprivation therapy in prostate cancer and their management
- (2015) Handoo Rhee et al. BJU INTERNATIONAL
- Adverse Effects of Androgen Deprivation Therapy and Strategies to Mitigate Them
- (2015) Paul L. Nguyen et al. EUROPEAN UROLOGY
- Molecular Characterization of Enzalutamide-treated Bone Metastatic Castration-resistant Prostate Cancer
- (2015) Eleni Efstathiou et al. EUROPEAN UROLOGY
- Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
- (2015) Christopher J. Sweeney et al. NEW ENGLAND JOURNAL OF MEDICINE
- Androgen receptor: structure, role in prostate cancer and drug discovery
- (2014) MH Eileen Tan et al. ACTA PHARMACOLOGICA SINICA
- Evolution of androgen receptor targeted therapy for advanced prostate cancer
- (2014) Yien Ning Sophia Wong et al. Nature Reviews Clinical Oncology
- AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
- (2014) Emmanuel S. Antonarakis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Luteinizing Hormone–Releasing Hormone Agonists: A Quick Reference for Prevalence Rates of Potential Adverse Effects
- (2013) Lauren M. Walker et al. Clinical Genitourinary Cancer
- Androgen receptors in hormone-dependent and castration-resistant prostate cancer
- (2013) Ayesha A. Shafi et al. PHARMACOLOGY & THERAPEUTICS
- Exercise maintains sexual activity in men undergoing androgen suppression for prostate cancer: a randomized controlled trial
- (2013) P Cormie et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Targeting the androgen receptor signalling axis in castration-resistant prostate cancer (CRPC)
- (2012) Che-Kai Tsao et al. BJU INTERNATIONAL
- ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
- (2012) N. J. Clegg et al. CANCER RESEARCH
- The androgen/androgen receptor axis in prostate cancer
- (2012) Eric G. Bluemn et al. CURRENT OPINION IN ONCOLOGY
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinically relevant fatigue in men with hormone-sensitive prostate cancer on long-term androgen deprivation therapy
- (2011) D. J. Storey et al. ANNALS OF ONCOLOGY
- Intragenic Rearrangement and Altered RNA Splicing of the Androgen Receptor in a Cell-Based Model of Prostate Cancer Progression
- (2011) Y. Li et al. CANCER RESEARCH
- Targeting Continued Androgen Receptor Signaling in Prostate Cancer
- (2011) C. Massard et al. CLINICAL CANCER RESEARCH
- Androgen receptor as a therapeutic target
- (2010) Wenqing Gao ADVANCED DRUG DELIVERY REVIEWS
- Regression of Castrate-Recurrent Prostate Cancer by a Small-Molecule Inhibitor of the Amino-Terminus Domain of the Androgen Receptor
- (2010) Raymond J. Andersen et al. CANCER CELL
- Drug resistance in metastatic castration-resistant prostate cancer
- (2010) Bostjan Seruga et al. Nature Reviews Clinical Oncology
- A phase III randomized, double-blind, placebo-controlled trial of gabapentin in the management of hot flashes in men (N00CB)
- (2009) C. L. Loprinzi et al. ANNALS OF ONCOLOGY
- Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial
- (2009) Jacques Irani et al. LANCET ONCOLOGY
- Redefining hormone resistance in prostate cancer
- (2009) Christopher J. Hoimes et al. Therapeutic Advances in Medical Oncology
- Splicing of a Novel Androgen Receptor Exon Generates a Constitutively Active Androgen Receptor that Mediates Prostate Cancer Therapy Resistance
- (2008) S. M. Dehm et al. CANCER RESEARCH
- Ligand-Independent Androgen Receptor Variants Derived from Splicing of Cryptic Exons Signify Hormone-Refractory Prostate Cancer
- (2008) R. Hu et al. CANCER RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started